Cheng X - Search Results

1

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.

Ni J, Cheng X, Zhou R, Zhao Q, Xu X, Guo W, Gu H, Chen C, Chen X. Ni J, et al. Among authors: cheng x. Front Oncol. 2021 Sep 6;11:724620. doi: 10.3389/fonc.2021.724620. eCollection 2021. Front Oncol. 2021. PMID: 34552876 Free PMC article.

2

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.

Ni J, Zhou R, Cheng X, Xu X, Guo W, Chen X. Ni J, et al. Among authors: cheng x. J Ovarian Res. 2020 Mar 17;13(1):29. doi: 10.1186/s13048-020-00629-4. J Ovarian Res. 2020. PMID: 32183851 Free PMC article.

3

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.

Ni J, Cheng X, Zhao Q, Dai Z, Xu X, Guo W, Gu H, Zhou R, Wang Y, Chen X. Ni J, et al. Among authors: cheng x. J Ovarian Res. 2021 May 17;14(1):68. doi: 10.1186/s13048-021-00803-2. J Ovarian Res. 2021. PMID: 33993885 Free PMC article.

4

Case Report: Extragonadal Yolk Sac Tumors Originating From the Endometrium and the Broad Ligament: A Case Series and Literature Review.

Cheng X, Zhao Q, Xu X, Guo W, Gu H, Zhou R, Chen C, Ma D, Wu Y, Ni J, Chen X. Cheng X, et al. Front Oncol. 2021 Jun 11;11:672434. doi: 10.3389/fonc.2021.672434. eCollection 2021. Front Oncol. 2021. PMID: 34211846 Free PMC article.

5

High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.

Guo W, He X, Ni J, Ma L, Cheng X, Wang C, Chen X, Wang Y. Guo W, et al. Among authors: cheng x. Front Oncol. 2021 Nov 23;11:761960. doi: 10.3389/fonc.2021.761960. eCollection 2021. Front Oncol. 2021. PMID: 34888242 Free PMC article.

6

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.

Ni J, Guo W, Zhao Q, Cheng X, Xu X, Zhou R, Gu H, Chen C, Chen X. Ni J, et al. Among authors: cheng x. Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571. eCollection 2021. Front Oncol. 2022. PMID: 35070965 Free PMC article.

7

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.

Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X. Ni J, et al. Among authors: cheng x. J Ovarian Res. 2019 Nov 28;12(1):117. doi: 10.1186/s13048-019-0594-1. J Ovarian Res. 2019. PMID: 31775908 Free PMC article.

8

The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial.

Gu H, Zhou R, Ni J, Xu X, Cheng X, Li Y, Chen X. Gu H, et al. Among authors: cheng x. J Ovarian Res. 2020 Jun 16;13(1):70. doi: 10.1186/s13048-020-00673-0. J Ovarian Res. 2020. PMID: 32546257 Free PMC article.

9

Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety.

Ni J, Cheng X, Chen J, Guo W, Dai Z. Ni J, et al. Among authors: cheng x. Onco Targets Ther. 2020 Oct 5;13:9857-9863. doi: 10.2147/OTT.S268613. eCollection 2020. Onco Targets Ther. 2020. PMID: 33116571 Free PMC article.

10

Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer.

Ni J, Wang Y, Cheng X, Teng F, Wang C, Han S, Chen X, Guo W. Ni J, et al. Among authors: cheng x. Cancer Manag Res. 2020 Nov 2;12:11085-11093. doi: 10.2147/CMAR.S277724. eCollection 2020. Cancer Manag Res. 2020. PMID: 33173341 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,118 results

Search Page

Filters